Al Blunt is an oncologist with over 25 years of experience in oncology drug development, specializing in solid tumors and hematologic malignancies primarily within the CRO setting. Currently serving as Vice President of Medical and Scientific Solutions at UBC, they have a strong background in phase I, II, and III clinical trials across various geographic regions. Previously, Al held executive roles at Covance, Advaxis, Inc., and Precision for Medicine, where they provided medical leadership, oversight, and strategic development for clinical programs and collaborations with regulatory authorities. Their expertise encompasses a wide range of cancer therapies, including cellular therapies and immunomodulatory drugs.
This person is not in any teams
This person is not in any offices